News Preview
Viatris To Acquire Pacira BioSciences: What Investors Should Know
Viatris has agreed to acquire Pacira BioSciences for $5.1 billion in cash and stock.
The acquisition is expected to boost Viatris' non-opioid pain management portfolio.
Want to stay up to date with the world events at sea or at home?
Explore Navvyx News - the best News app for seafarers.